OL
CPRX

Odyssean LLC’s Catalyst Pharmaceutical CPRX Stock Holding History

Odyssean LLC’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$475K Sell
19,184
-12,030
-39% -$287K 0.17% 212
2025
Q4 		$729K Buy
+31,214
New +$695K 0.52% 115

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Odyssean LLC's CPRX Position: Q1 2026 in Review

Odyssean LLC reduced its Catalyst Pharmaceutical (CPRX) stake by 39% in Q1 2026, selling an estimated $287K and leaving 19,184 shares worth $475K. The position accounts for 0.17% of the portfolio, ranked #212.

Odyssean LLC first reported a position in CPRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $729K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Odyssean LLC held 19,184 shares of Catalyst Pharmaceutical worth $475K as of Q1 2026.
  • Odyssean LLC sold 12,030 Catalyst Pharmaceutical shares in Q1 2026, an estimated $287K.
  • Catalyst Pharmaceutical made up 0.17% of Odyssean LLC's portfolio in Q1 2026, its #212 holding.
  • Odyssean LLC first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • Odyssean LLC's Catalyst Pharmaceutical position peaked at $729K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Odyssean LLC's 13F filing for Q1 2026, filed 15 May 2026.